Endocrine therapy adherence and 10-year cardiometabolic risk in hormone receptor-positive breast cancer
JNCI Cancer Spectrum · 02.11.2026 · 10 (6)
DOI: 10.1093/jncics/pkag095 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 24.09.2026. Verfasst von Jorge R Ledesma und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents, Hormonal, Hypertension, Tamoxifen. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Background
Adjuvant endocrine therapy (AET) reduces breast cancer (BC) recurrence but may adversely affect cardiometabolic health. We evaluated the association between AET adherence duration and 10-year risk of hypertension, dyslipidemia, diabetes, and mortality among postmenopausal women with early-stage hormone receptor-positive BC.
Methods
We conducted a prospective cohort study of 8365 postmenopausal women with stage I-III hormone receptor-positive BC within Kaiser Permanente Northern California who initiated AET between 2005 and 2013. Adherence (proportion of days covered >80%) was assessed annually using prescription dispensing data. We estimated 10-year cumulative incidence (CI) under 6 adherence duration strategies (0-5 years) using sequentially doubly robust estimation, adjusting for demographic, clinical, lifestyle, and tumor characteristics. Analyses were stratified by AET type (aromatase inhibitor [AI]; tamoxifen [TAM]).
Results
Overall, 42.7% were adherent for ≥5 years. Compared with nonadherence, 5-year adherence was associated with higher 10-year CI of hypertension (absolute CI difference = 8.81% [95% confidence interval: 4.25 to 13.4]), dyslipidemia (5.16% [0.31 to 10.0]), and diabetes (2.58% [0.02 to 5.14]) but lower all-cause death (10.7% [7.74 to 13.7]) and BC-specific death (5.37% [3.36 to 7.38]). Five-year AI adherence was associated with increased hypertension (9.37% [4.54 to 14.2]), dyslipidemia (6.84% [1.76 to 11.9]), and diabetes (3.29% [0.58 to 6.00]), whereas TAM adherence was associated only with hypertension (9.37% [4.54 to 14.2]). AI adherence was associated with higher dyslipidemia risk than TAM (9.86% [5.09 to 14.6]).
Conclusions
AI adherence was associated with increased cardiometabolic risk, whereas TAM was associated only with hypertension risk. Despite these risks, AET was associated with improved survival. Further research should evaluate whether cardiometabolic risk factors influence cardiovascular events among BC survivors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States.
- Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA, United States.
- Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA, United States.
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
- Cancer Prevention Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
- Division of Cardiology, Kaiser Permanente Northern California, South San Francisco, CA, United States.
ORCID-Profile: Jorge R Ledesma, Sayan Dasgupta, Heather Greenlee, Raymond Liu
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Ledesma, J. R., Nugent, J., Cheng, R., Specht, J. M., Laurent, C. A., Roh, J., Dasgupta, S., Meisner, A., Thadani, S. R., Greenlee, H., Liu, R., & Kwan, M. L. (2026). Endocrine therapy adherence and 10-year cardiometabolic risk in hormone receptor-positive breast cancer. JNCI Cancer Spectrum, 10(6). https://doi.org/10.1093/jncics/pkag095
Vancouver
Ledesma JR, Nugent J, Cheng R, Specht JM, Laurent CA, Roh J, et al. Endocrine therapy adherence and 10-year cardiometabolic risk in hormone receptor-positive breast cancer. JNCI Cancer Spectrum. 2026;10(6). doi:10.1093/jncics/pkag095
BibTeX
@article{Ledesma2026,
author = {Ledesma, Jorge R and Nugent, Joshua and Cheng, Richard and Specht, Jennifer M and Laurent, Cecile A and Roh, Janise and Dasgupta, Sayan and Meisner, Allison and Thadani, Samir R and Greenlee, Heather and Liu, Raymond and Kwan, Marilyn L},
title = {Endocrine therapy adherence and 10-year cardiometabolic risk in hormone receptor-positive breast cancer},
journal = {JNCI Cancer Spectrum},
year = {2026},
volume = {10},
number = {6},
doi = {10.1093/jncics/pkag095}
}
EUVIMED